MRD blood test to guide treatment in lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial uses a blood test (ctDNA and CTC) to check for minimal residual disease (MRD) after treatment for stage IIA-IIIC non-small cell lung cancer. The goal is to see if MRD can help predict whether the cancer will come back and guide decisions on extra treatment to prevent recurrence.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have stage IIA to IIIC non-small cell lung cancer (NSCLC) that has not been treated for advanced disease.
- You have not had surgery, chemotherapy, or radiation before surgery for your lung cancer.
- You have not received cellular therapy (like special immune cell treatments) in the last year.
- You are generally healthy enough to undergo treatment (ECOG score 0-1, and expected survival more than 3 months).
- You have at least one tumor that can be measured on imaging scans.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is testing whether a simple blood test (called ctDNA-MRD) can help guide treatment for people with advanced lung cancer that has not spread far. You would receive chemotherapy plus immunotherapy before surgery, and the blood test may help doctors understand how well the treatment is working.
This study uses a blood test called ctDNA to look for leftover lung cancer after surgery. Based on that result, the trial will help decide which treatment approach is best for you and may catch cancer returning earlier.
This trial uses a blood test to look for tiny bits of cancer DNA after treatment. It may help find early signs that lung cancer has come back, so doctors can act sooner.
This trial studies if a blood test that looks for tumor DNA combined with a PET-CT scan can better predict if lung cancer has spread to lymph nodes. It may help guide treatment decisions for people with non-small cell lung cancer that hasn't been treated yet.
This trial tests whether a simple blood test (ctDNA) can help doctors decide if you need radiation therapy after lung cancer surgery. The goal is to tailor your treatment to your individual risk, possibly avoiding extra radiation if you don't need it.
This study uses a special blood test to look for tiny traces of lung cancer after surgery. It aims to find “minimal residual disease,” meaning cancer cells that may still be hiding after your tumor is removed.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.